SCHEMBL8230291

SCHEMBL8230291

Nc1cccc(/N=C2\C(=O)N(c3ccccc3)c3ccccc32)c1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 12/20 0.70
HTR4 Q13639 1/20 0.70
MAPT P10636 4/20 0.50
KMT2A Q03164 3/20 0.50
TTR P02766 1/20 0.50
MEN1 O00255 1/20 0.50
NPSR1 Q6W5P4 2/20 0.49
CES2 O00748 1/20 0.49
ALDH1A1 P00352 1/20 0.49
BCHE P06276 1/20 0.49
GAA P10253 1/20 0.49
CES1 P23141 1/20 0.49
DRD5 P21918 2/20 0.46
ADRA1A P35348 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
HSPA1A P0DMV8 1/20 0.46
PABPC1 P11940 1/20 0.46
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL916818 0.85 GALR3 (0.68) GALR3HTR4MAPTKMT2ATTR
SCHEMBL916817 0.85 GALR3 (0.68) GALR3HTR4MAPTKMT2ATTR
SCHEMBL916454 0.85 GALR3 (0.68) GALR3HTR4MAPTKMT2ATTR
SCHEMBL917358 0.85 GALR3 (0.72) GALR3HTR4MAPTKMT2ATTR
SCHEMBL916453 0.85 GALR3 (0.68) GALR3HTR4MAPTKMT2ATTR
SCHEMBL917357 0.85 GALR3 (0.72) GALR3HTR4MAPTKMT2ATTR
SCHEMBL916941 0.82 GALR3 (0.64) GALR3HTR4MAPTKMT2ATTR
SCHEMBL916940 0.82 GALR3 (0.64) GALR3HTR4MAPTKMT2ATTR
SCHEMBL13495845 0.82 GALR3 (0.78) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL916990 0.82 GALR3 (1.00) GALR3HTR4DRD5ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2241316-A1 Indolone compounds useful to treat cognitive impairment Helicon Therapeutics, Inc. (US) 2010-10-20 EP disclosed
EP-1957067-B1 INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT HELICON THERAPEUTICS INC (US) 2010-09-08 EP disclosed
WO-2008002946-A2 METHOD OF MODULATING NEURITE OUTGROWTH BY THE USE OF A GALANIN-3 RECEPTOR ANTAGONIST HELICON THERAPEUTICS, INC. (US) 2008-01-03 WO disclosed
WO-2007070362-A1 INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT HELICON THERAPEUTICS, INC. (US) 2007-06-21 WO disclosed
WO-2004093789-A2 USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2004-11-04 WO disclosed